Mostrar el registro sencillo del ítem

dc.contributor.authorLópez Garzón, María de la Cabeza 
dc.contributor.authorCanta, Annalisa
dc.contributor.authorChiorazzi, Alessia
dc.contributor.authorAlberti, Paola
dc.date.accessioned2023-11-13T12:08:01Z
dc.date.available2023-11-13T12:08:01Z
dc.date.issued2023-10-15
dc.identifier.citationM. Lopez-Garzon et al. Gait analysis in chemotherapy-induced peripheral neurotoxicity rodent models. Brain Research Bulletin 203 (2023) 110769. [https://doi.org/10.1016/j.brainresbull.2023.110769]es_ES
dc.identifier.urihttps://hdl.handle.net/10481/85628
dc.descriptionMLG has received funding for its training with the grant FI19/00230 and MV22/00095 by the Fondo de Investigacion Sanitaria del Instituto de Salud Carlos III (Spain).es_ES
dc.description.abstractGait analysis could be used in animal models as an indicator of sensory ataxia due to chemotherapy-induced peripheral neurotoxicity (CIPN). Over the years, gait analysis in in vivo studies has evolved from simple observations carried out by a trained operator to computerised systems with machine learning that allow the quantification of any variable of interest and the establishment of algorithms for behavioural classification. However, there is not a consensus on gait analysis use in CIPN animal models; therefore, we carried out a systematic review. Of 987 potentially relevant studies, 14 were included, in which different methods were analysed (observation, footprint and CatWalk™). We presented the state-of-the-art of possible approaches to analyse sensory ataxia in rodent models, addressing advantages and disadvantages of different methods available. Semi-automated methods may be of interest when preventive or therapeutic strategies are evaluated, also considering their methodological simplicity and automaticity; up to now, only CatWalk™ analysis has been tested. Future studies should expect that CIPN-affected animals tend to reduce hind paw support due to pain, allodynia or loss of sensation, and an increase in swing phase could or should be observed. Few available studies documented these impairments at the last time point, and only appeared later on respect to other earlier signs of CIPN (such as altered neurophysiological findings). For that reason, gait impairment could be interpreted as late repercussions of loss of sensory.es_ES
dc.description.sponsorshipInstituto de Salud Carlos III FI19/00230, MV22/00095es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectChemotherapy-induced peripheral neuropathyes_ES
dc.subjectChemotherapy-induced peripheral neurotoxicityes_ES
dc.subjectGait analysises_ES
dc.subjectAnimal modelses_ES
dc.subjectSensory ataxiaes_ES
dc.subjectPhysical therapy es_ES
dc.subjectCat Walk™es_ES
dc.subjectNeuropathyes_ES
dc.titleGait analysis in chemotherapy-induced peripheral neurotoxicity rodent modelses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.1016/j.brainresbull.2023.110769
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional